Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SUPN
  • CUSIP: 86845910
  • Web:
  • Market Cap: $2.0888 billion
  • Outstanding Shares: 50,699,000
Average Prices:
  • 50 Day Moving Avg: $43.22
  • 200 Day Moving Avg: $39.46
  • 52 Week Range: $17.25 - $50.04
  • Trailing P/E Ratio: 20.79
  • Foreward P/E Ratio: 24.73
  • P/E Growth: 1.47
Sales & Book Value:
  • Annual Revenue: $252.59 million
  • Price / Sales: 8.24
  • Book Value: $4.52 per share
  • Price / Book: 9.08
  • EBITDA: $82.36 million
  • Net Margins: 41.10%
  • Return on Equity: 30.73%
  • Return on Assets: 19.48%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 1.94%
  • Quick Ratio: 1.74%
  • Average Volume: 742,050 shs.
  • Beta: 1.3
  • Short Ratio: 7.53

Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to analysts' expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. View Supernus Pharmaceuticals' Earnings History.

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 12-month price targets for Supernus Pharmaceuticals' stock. Their predictions range from $41.00 to $51.00. On average, they expect Supernus Pharmaceuticals' share price to reach $47.50 in the next twelve months. View Analyst Ratings for Supernus Pharmaceuticals.

What are analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
  • 2. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (7/18/2017)
  • 3. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:

  • Charles W. Newhall III, Independent Chairman of the Board
  • Jack A. Khattar, President, Chief Executive Officer, Secretary, Director
  • Gregory S. Patrick, Chief Financial Officer, Vice President
  • Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer
  • Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer
  • Victor Vaughn, Senior Vice President - Sales and Marketing
  • Georges Gemayel Ph.D., Independent Director
  • Frederick M. Hudson CPA, Independent Director
  • William A. Nuerge, Independent Director
  • John M. Siebert Ph.D., Independent Director

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $41.05.

MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $47.50 (15.71% upside)
Consensus Price Target History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Price Target History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/27/2017Cantor FitzgeraldReiterated RatingBuy$49.00LowView Rating Details
9/26/2017Piper Jaffray CompaniesReiterated RatingHold$41.00LowView Rating Details
9/21/2017Cowen and CompanyReiterated RatingBuy$50.00LowView Rating Details
9/20/2017Jefferies Group LLCReiterated RatingBuy$51.00HighView Rating Details
9/20/2017Janney Montgomery ScottReiterated RatingHold$47.00LowView Rating Details
9/19/2017Stifel NicolausDowngradeBuy -> Hold$47.00HighView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017$0.24$0.32$68.54 million$75.83 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
2017 EPS Consensus Estimate: $0.97
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.16$0.24$0.20
Q2 20172$0.23$0.25$0.24
Q3 20172$0.27$0.29$0.28
Q4 20172$0.23$0.26$0.25
(Data provided by Zacks Investment Research)


Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 95.36%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2017Gregory S. PatrickCFOSell50,000$47.60$2,380,000.00View SEC Filing  
9/8/2017Padmanabh P BhattSVPSell5,000$49.86$249,300.00View SEC Filing  
9/7/2017Stefan K.F. SchwabeInsiderSell95,000$46.59$4,426,050.00View SEC Filing  
8/16/2017Padmanabh P BhattVPSell3,709$45.23$167,758.07View SEC Filing  
7/12/2017Padmanabh P BhattVPSell3,735$44.90$167,701.50View SEC Filing  
6/23/2017Padmanabh P BhattVPSell2,556$44.90$114,764.40View SEC Filing  
6/2/2017Padmanabh P BhattVPSell10,000$39.86$398,600.00View SEC Filing  
5/26/2017Padmanabh P BhattVPSell2,500$35.90$89,750.00View SEC Filing  
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.00View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.00View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.54View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Supernus Pharmaceuticals (NASDAQ:SUPN)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateHeadline logoCritical Review: Supernus Pharmaceuticals (SUPN) vs. The Competition - October 13 at 8:26 AM logoThis Company’s Sales Have Grown 1,700% in Just Three Years - October 12 at 3:45 PM logoCritical Survey: Supernus Pharmaceuticals (SUPN) versus Novan (NOVN) - October 12 at 2:34 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Rating of "Buy" from Analysts - October 11 at 4:42 PM logoGeneric Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Allergan - PR Newswire (press release) - October 10 at 7:15 AM logoMedical Drug Stocks: What Are The Best Wealth Builders Now? - October 7 at 8:52 AM logoETFs with exposure to Supernus Pharmaceuticals, Inc. : October 6, 2017 - October 7 at 8:52 AM logoSupernus Pharmaceuticals (SUPN) & Its Competitors Head-To-Head Analysis - October 7 at 2:08 AM logoSupernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017 - October 3 at 1:09 PM logoETFs with exposure to Supernus Pharmaceuticals, Inc. : September 26, 2017 - October 3 at 1:09 PM logoSupernus Pharmaceuticals' (SUPN) Hold Rating Reiterated at Piper Jaffray Companies - October 1 at 7:40 PM logoComparing Supernus Pharmaceuticals (SUPN) & Mallinckrodt PLC (MNK) - September 29 at 12:30 AM logoJim Cramer Weighs In On Emerge Energy Services LP And Supernus Pharmaceuticals - Benzinga - September 27 at 10:43 PM logoCantor Fitzgerald Reaffirms "Buy" Rating for Supernus Pharmaceuticals, Inc. (SUPN) - September 27 at 7:28 PM logoContrasting Supernus Pharmaceuticals (SUPN) & Mallinckrodt PLC (MNK) - September 27 at 12:56 AM logoAnalyzing Supernus Pharmaceuticals (SUPN) and The Competition - September 26 at 4:28 PM logoSupernus Pharmaceuticals' (SUPN) Buy Rating Reiterated at Cantor Fitzgerald - September 24 at 9:08 PM logoSupernus Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark - September 23 at 9:29 AM logoSupernus Pharmaceuticals, Inc. (SUPN) Rating Reiterated by Cowen and Company - September 21 at 4:28 PM logoJanney Montgomery Scott Reaffirms Hold Rating for Supernus Pharmaceuticals, Inc. (SUPN) - September 20 at 6:24 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Rating Reiterated by Jefferies Group LLC - September 20 at 5:46 PM logoSupernus Pharmaceuticals Inc. (SUPN) Sank To A 3-Month Low - September 20 at 9:39 AM logoWhy Supernus Pharmaceuticals' Shares Plummeted 23.4% Today - September 20 at 9:39 AM logoToday's Research Reports on Stocks to Watch: Capricor Therapeutics and Supernus Pharmaceuticals - September 20 at 9:39 AM logoSupernus Pharmaceuticals Inc (SUPN) Downgraded to Hold at Stifel Nicolaus - September 20 at 12:46 AM logoSupernus Pharma (SUPN) Reports Update on SPN-810 Phase III Clinical Trials - September 19 at 8:11 AM logoSupernus Pharmaceuticals Inc. (SUPN) Is Falling After Study Update - September 19 at 8:11 AM logoSupernus Provides Update on SPN-810 Phase III Clinical Trials - September 19 at 8:11 AM logoSupernus shares decline on drug study change - September 19 at 8:11 AM logoComparing Supernus Pharmaceuticals (SUPN) and Its Rivals - September 17 at 8:30 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Given Consensus Rating of "Buy" by Analysts - September 16 at 4:54 PM logoStefan K.F. Schwabe Sells 95,000 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock - September 11 at 10:20 PM logoInsider Selling: Supernus Pharmaceuticals, Inc. (SUPN) CFO Sells 50,000 Shares of Stock - September 11 at 10:20 PM logoSupernus Pharmaceuticals, Inc. (SUPN) SVP Sells $249,300.00 in Stock - September 11 at 10:20 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Given "Hold" Rating at Piper Jaffray Companies - September 9 at 3:06 PM logoTechnical Snapshots for These Generic Drugs Stocks -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Lannett - September 5 at 8:55 AM logoReviewing Advanced Accelerator Applications (AAAP) and Supernus Pharmaceuticals (SUPN) - September 3 at 8:30 PM logoReviewing Supernus Pharmaceuticals (SUPN) & AbbVie (ABBV) - August 30 at 12:18 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $77.74 Million - August 27 at 3:34 AM logo Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Announce Earnings of $0.27 Per Share - August 25 at 4:28 PM logoIs Supernus Becoming The Leader In ADHD Non-Stimulants? - Seeking Alpha - August 24 at 1:30 PM logoSupernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Recommendation of "Buy" from Analysts - August 22 at 4:36 PM logoRockville's Supernus Pharmaceuticals wins patents dispute trial - August 19 at 7:54 AM logoContrasting AbbVie (ABBV) and Supernus Pharmaceuticals (SUPN) - August 19 at 6:34 AM logoForm 8-K SUPERNUS PHARMACEUTICALS For: Aug 15 - August 18 at 7:36 AM logoPadmanabh P. Bhatt Sells 3,709 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock - August 16 at 10:44 PM logoSupernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : August 15, 2017 - August 16 at 7:54 AM logoSupernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : August 15, 2017 - August 16 at 7:54 AM logoSupernus Defeats Second Generic Challenger to Oxtellar XR® - August 15 at 5:23 PM logoAnalysts Set Expectations for Supernus Pharmaceuticals, Inc.'s Q4 2017 Earnings (SUPN) - August 14 at 6:20 AM



Supernus Pharmaceuticals (SUPN) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.